Acute Myeloid Leukemia Therapeutics Market - Forecast(2021 - 2026)

Report Code: HCR 18488 Report Format: PDF + Excel (Delivery in 48 Hrs)

Acute Myeloid Leukemia Therapeutics Market Overview

Acute Myeloid Leukemia Therapeutics market size is forecast to reach $18.3 billion by 2026, growing at a CAGR of 7.2% during the forecast period 2021-2026. Leukemia affects the white blood cells and bone marrow. It is characterized by the rapid increase of abnormal blood cells growth that reduces the numbers of fully modified blood cells which leads to the typical symptoms of anemia, bleeding, and high risk of infection. Leukemia can grow along the lymphoid stem cell lines or myeloid depending upon the epigenetic and genetic mutations of the pluripotent stem cells. The leukemia that occurs along the myeloid are known as acute myeloid leukemia and it is a serious condition that is suffered by adult people. Various types of treatments that includes cytarabine, mitoxantrone, tyrosine kinase inhibitors, and imatinib among others are used for acute myeloid leukemia therapeutics. Increasing prevalence of acute myeloid leukemia and increased drug approval rate for acute myeloid leukemia are the major factors driving the growth of the market. Large number of treatment options available for treatment of acute myeloid leukemia and increasing funding for cancer research & development of new therapies is set to further enhance the overall market development of the Acute Myeloid Leukemia Therapeutics Market for the period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Report Coverage

The report: Acute Myeloid Leukemia Therapeutics Market Forecast (2021-2026), by Industry ARC, covers an in-depth analysis of the following segments of the Acute Myeloid Leukemia Therapeutics Market.

By Treatment Type: Cytarabine, Anthracycline Drugs, Daunomycin, Idarubicin, Mitoxantrone, Alkylating Agents, Anti Metabolites, Hormonal Therapy, Tyrosine Kinase Inhibitors, Dasatinib, Imatinib, and Others
By Gender: Male, and Female
By End User: Hospitals, Retail Drug Stores, Ambulatory Care Centers, and Clinics
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (Middle East, and Africa)

Key Takeaways

  • North America dominated the Acute Myeloid Leukemia Therapeutics Market in 2020 owing to the increasing research in field of regenerative medicine for treatment of acute myeloid leukemia and growing awareness on personalised medicines. The Acute Myeloid Leukemia Therapeutics Market scope for different regions will be provided in the final report.
  • Increasing advantages of biopharmaceuticals over conventional medicines and strong biopharmaceuticals pipeline are likely to aid the market growth of the Acute Myeloid Leukemia Therapeutics Market report.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Acute Myeloid Leukemia Therapeutics Market report.
  • High cost of the therapeutics process and its safety concerns is poised to create hurdles for the Acute Myeloid Leukemia Therapeutics Market.

Acute Myeloid Leukemia Therapeutics Market Revenue Share, By Geography, 2020(%)

For More Details on This Report - Request for Sample

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By Treatment Type

Cytarabine held the largest share in the Acute Myeloid Leukemia Therapeutics Market in 2020 and is estimated to grow at a CAGR 7.7% during the forecast period 2021-2026. Cytarabine is used for the treatment of different types of leukemia such as acute and chronic myeloid leukemia among others. Owing to its effectiveness in the treatment of acute myeloid leukemia, it is being widely used during chemotherapy process. Macmillan Cancer Support, an organization that is working for cancer have stated that cytarabine is more effective for the treatment of acute myeloid treatment. Chemotherapy kills the cancer cells that metastasized across the different parts of the body. Cytarabine is estimated to register the highest CAGR over the period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By End User

Hospitals held the largest share in the Acute Myeloid Leukemia Therapeutics Market in 2020 and is estimated to grow at a CAGR 7.4% during the forecast period 2021-2026. Chemotherapy is majorly used for consolidation therapy of acute myeloid leukemia. In hospitals, younger adults are given mainly four rounds of high or immediate dose of cytarabine at monthly intervals and several different regimes are used for older patients. Chemotherapy is usually given in the hospital and recovery time can be spent at home. Hospitals are estimated to register the highest CAGR over the forecast period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Segment Analysis – By Geography

North America dominated the Acute Myeloid Leukemia Therapeutics Market with a major share of 38.3% in 2020. This is attributed to the increasing research in the field of regenerative medicine for treatment of acute myeloid leukemia. Growing awareness on personalized medicine, high incidences of leukemia, and huge investment in the development of pipeline drug is also increasing the growth of the market in this region.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the rising investment and increasing cancer awareness. Improving healthcare infrastructure and increasing inclination towards targeted therapies is also increasing the growth of the market in this region.

Acute Myeloid Leukemia Therapeutics Market Drivers

Increasing prevalence of acute myeloid leukemia

Increasing prevalence of acute myeloid leukemia is increasing the growth of the Acute Myeloid Leukemia Therapeutics Market. Acute Myeloid Leukemia begins in the bone marrow and quickly moves into the blood. It can also spread to other parts of the body such as liver, spleen, testicles, and central nervous system. It develops from those cells that turns into white blood cells. Radiation therapy or surgery in cancer patients removes the cancer cells in a specific area but chemotherapy works through the body and gives a better result. According to the estimation done by The American Cancer Society, around 61,780 new cases and 22,840 deaths from leukemia has been reported in 2019.Thus, increasing the growth of the Acute Myeloid Leukemia Therapeutics Market during the forecast period 2021-2026.

Increasing Cancer Awareness

Increasing cancer awareness is increasing the growth of the Acute Myeloid Leukemia Therapeutics Market. This is attributed to the fact that according to the World Health Organization, one third of all cancers are preventable and this can be done by taking a free cancer risk test that identifies the behaviors that can lead to cancer and ways to reduce the risk. As of 2019, 16.9 million cancer survivors are there in U.S. and number of cancer survivors are set to increase to 22.2 million by 2030.Thus, increasing the growth of the Acute Myeloid Leukemia Therapeutics Market during the forecast period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Challenges

High Cost of the Therapeutics Process and its Safety Concerns

Some of the factors that are set to impede the growth of the Acute Myeloid Leukemia Therapeutics Market are high cost of the therapeutics process and its safety concerns. Lack of targeted therapies in current acute myeloid leukemia therapeutics and difficult approval process for drugs is also set to hinder the growth of the market during the forecast period 2021-2026.

Acute Myeloid Leukemia Therapeutics Market Landscape

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Acute Myeloid Leukemia Therapeutics Market. In 2020, the Acute Myeloid Leukemia Therapeutics Market share is consolidated by the top ten players present in the market. Acute Myeloid Leukemia Therapeutics Market, top 10 companies are Pfizer Inc., Eisai Inc., Cephalon Inc., Celegene Corporation, Bristol,, Novartis AG, Genzyme Corporation, Eli Lily & Company, Amgen, and Gilead Sciences among others.

Relevant Reports

Report Code: HCR 72534

B-cell Chronic Lymphocytic Leukemia Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2019 - 2024

Report Code: HCR 69731

For more Lifesciences and Healthcare Market reports, please click here

1. Acute Myeloid Leukemia Therapeutics Market- Overview
    1.1 Definitions and Scope
2. Acute Myeloid Leukemia Therapeutics Market- Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Treatment Type
    2.3 Key trends by Gender
    2.4 Key trends by End User
    2.5 Key trends by Geography
3. Acute Myeloid Leukemia Therapeutics Market– Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Acute Myeloid Leukemia Therapeutics Market- Startup Companies Scenario Premium
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Acute Myeloid Leukemia Therapeutics Market– Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Acute Myeloid Leukemia Therapeutics Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Acute Myeloid Leukemia Therapeutics Market– Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Acute Myeloid Leukemia Therapeutics Market– By Treatment Type (Market Size –$Million/$Billion)
    8.1 Cytarabine
    8.2 Anthrocycline Drugs
        8.2.1 Daunomycin
        8.2.2 Idarubicin
        8.2.3 Mitocantrone
    8.3 Alkylating Agents
    8.4 Anti-Metabolites
    8.5 Hormonal Therapy
    8.6 Tyrosine Kinase Inhibitors
        8.6.1 Dasatinib
        8.6.2 Imatinib
    8.7 Others
9. Acute Myeloid Leukemia Therapeutics Market– By Gender(Market Size –$Million/$Billion)
    9.1 Male
    9.2 Female
10. Acute Myeloid Leukemia Therapeutics Market– By End User (Market Size –$Million/$Billion)
    10.1 Hospital
    10.2 Retail Drug Stores
    10.3 Ambulatory Care Centers
    10.4 Clinics
11. Acute Myeloid Leukemia Therapeutics Market- By Geography(Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Mexico
        11.1.3 Canada
    11.2 Europe
        11.2.1 U.K.
        11.2.2 France
        11.2.3 Germany
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Acute Myeloid Leukemia Therapeutics Market- Entropy
13. Acute Myeloid Leukemia Therapeutics Market– Industry/Segment Competition Landscape Premium
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Acute Myeloid Leukemia Therapeutics Market– Key Company List by Country Premium Premium
15. Acute Myeloid Leukemia Therapeutics Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
1.2 Anthracycline Drugs Market 2019-2024 ($M) - Global Industry Research
1.2.1 Daunomycin Market 2019-2024 ($M)
1.2.2 Idarubicin Market 2019-2024 ($M)
1.2.3 Mitoxantrone Market 2019-2024 ($M)
1.3 Hormonal Therapy Market 2019-2024 ($M) - Global Industry Research
2.Global ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
2.1 Oral Drugs Market 2019-2024 ($M) - Global Industry Research
2.2 Intravenous Drugs Market 2019-2024 ($M) - Global Industry Research
3.Global ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 (Volume/Units)
3.2 Anthracycline Drugs Market 2019-2024 (Volume/Units) - Global Industry Research
3.2.1 Daunomycin Market 2019-2024 (Volume/Units)
3.2.2 Idarubicin Market 2019-2024 (Volume/Units)
3.2.3 Mitoxantrone Market 2019-2024 (Volume/Units)
3.3 Hormonal Therapy Market 2019-2024 (Volume/Units) - Global Industry Research
4.Global ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 (Volume/Units)
4.1 Oral Drugs Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Intravenous Drugs Market 2019-2024 (Volume/Units) - Global Industry Research
5.North America ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
5.2 Anthracycline Drugs Market 2019-2024 ($M) - Regional Industry Research
5.2.1 Daunomycin Market 2019-2024 ($M)
5.2.2 Idarubicin Market 2019-2024 ($M)
5.2.3 Mitoxantrone Market 2019-2024 ($M)
5.3 Hormonal Therapy Market 2019-2024 ($M) - Regional Industry Research
6.North America ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
6.1 Oral Drugs Market 2019-2024 ($M) - Regional Industry Research
6.2 Intravenous Drugs Market 2019-2024 ($M) - Regional Industry Research
7.South America ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
7.2 Anthracycline Drugs Market 2019-2024 ($M) - Regional Industry Research
7.2.1 Daunomycin Market 2019-2024 ($M)
7.2.2 Idarubicin Market 2019-2024 ($M)
7.2.3 Mitoxantrone Market 2019-2024 ($M)
7.3 Hormonal Therapy Market 2019-2024 ($M) - Regional Industry Research
8.South America ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
8.1 Oral Drugs Market 2019-2024 ($M) - Regional Industry Research
8.2 Intravenous Drugs Market 2019-2024 ($M) - Regional Industry Research
9.Europe ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
9.2 Anthracycline Drugs Market 2019-2024 ($M) - Regional Industry Research
9.2.1 Daunomycin Market 2019-2024 ($M)
9.2.2 Idarubicin Market 2019-2024 ($M)
9.2.3 Mitoxantrone Market 2019-2024 ($M)
9.3 Hormonal Therapy Market 2019-2024 ($M) - Regional Industry Research
10.Europe ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
10.1 Oral Drugs Market 2019-2024 ($M) - Regional Industry Research
10.2 Intravenous Drugs Market 2019-2024 ($M) - Regional Industry Research
11.APAC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
11.2 Anthracycline Drugs Market 2019-2024 ($M) - Regional Industry Research
11.2.1 Daunomycin Market 2019-2024 ($M)
11.2.2 Idarubicin Market 2019-2024 ($M)
11.2.3 Mitoxantrone Market 2019-2024 ($M)
11.3 Hormonal Therapy Market 2019-2024 ($M) - Regional Industry Research
12.APAC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
12.1 Oral Drugs Market 2019-2024 ($M) - Regional Industry Research
12.2 Intravenous Drugs Market 2019-2024 ($M) - Regional Industry Research
13.MENA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY TYPE Market 2019-2024 ($M)
13.2 Anthracycline Drugs Market 2019-2024 ($M) - Regional Industry Research
13.2.1 Daunomycin Market 2019-2024 ($M)
13.2.2 Idarubicin Market 2019-2024 ($M)
13.2.3 Mitoxantrone Market 2019-2024 ($M)
13.3 Hormonal Therapy Market 2019-2024 ($M) - Regional Industry Research
14.MENA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION Market 2019-2024 ($M)
14.1 Oral Drugs Market 2019-2024 ($M) - Regional Industry Research
14.2 Intravenous Drugs Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
2.Canada Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
3.Mexico Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
4.Brazil Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
5.Argentina Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
6.Peru Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
7.Colombia Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
8.Chile Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
9.Rest of South America Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
10.UK Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
11.Germany Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
12.France Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
13.Italy Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
14.Spain Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
15.Rest of Europe Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
16.China Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
17.India Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
18.Japan Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
19.South Korea Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
20.South Africa Acute Myeloid Leukemia Therapeutics Market Revenue, 2019-2024 ($M)
21.North America Acute Myeloid Leukemia Therapeutics By Application
22.South America Acute Myeloid Leukemia Therapeutics By Application
23.Europe Acute Myeloid Leukemia Therapeutics By Application
24.APAC Acute Myeloid Leukemia Therapeutics By Application
25.MENA Acute Myeloid Leukemia Therapeutics By Application
26.Ambit Biosciences Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Celgene Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Teva Pharmaceutical Industries Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Clavis Pharma ASA, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Eisai Co., Ltd., Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Sanofi, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Sunesis Pharmaceuticals, Inc., Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Novartis AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Bristol-Myers Squibb, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.F. Hoffmann-La Roche AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)